公开(公告)号：US08372452B2

公开(公告)日：2013-02-12

申请号：US13001268

申请日：2009-06-25

申请人： Vijay Singh Chauhan ,  Kavita Sujeet Salkar

发明人： Vijay Singh Chauhan ,  Kavita Sujeet Salkar

IPC分类号： A61K36/67 ,  A61K36/00

CPC分类号： A61K36/67

摘要： An oral herbal composition comprising a therapeutically effective amount of an extract derived from the berries of a plant, Piper cubeba, wherein the composition is provided for use in the treatment of oral candidiasis (oral thrush). The oral herbal composition can be formulated in the form of a candy, a chewable tablet and an oral gel. The herbal composition exhibits antifungal activity against azole resistant strains of Candida albicans. The herbal composition is safe to administer and has improved patient compliance.

摘要翻译： 一种口服草药组合物，其包含治疗有效量的源自植物浆果（Piper cubeba）的提取物，其中所述组合物用于治疗口腔念珠菌病（口服鹅口疮）。 口服草药组合物可以以糖，咀嚼片和口服凝胶的形式配制。 草药组合物对白色念珠菌的抗唑菌株表现出抗真菌活性。 草药组合物可安全施用，并改善了患者的依从性。

公开(公告)号：US20130017264A1

公开(公告)日：2013-01-17

申请号：US13183598

申请日：2011-07-15

申请人： Jayant J. KHANDARE ,  Sanjay P. Boldhane

发明人： Jayant J. KHANDARE ,  Sanjay P. Boldhane

IPC分类号： A61K9/00 ,  A61K47/26 ,  B05D3/10 ,  A61P39/00

CPC分类号： A61K9/0065 ,  A61K9/0092 ,  A61K47/36

摘要： A drug delivery system which comprises alginate tube that is prepared by coating a substrate with alginate gel. One or more therapeutic drugs may also be present in the alginate gel or in the cavity of the tube. The activity of the alginate drug delivery system is highly adjustable so that the release may be controlled as required. The rate at which the system releases the drug and the concentration of the drug released can be adjusted by varying; the number of layers of the alginate tubes, the number of open or closed ends of the tubes, or the number of tube layers containing the drug.

摘要翻译： 一种药物递送系统，其包含通过用藻酸盐凝胶涂覆底物制备的藻酸盐管。 一种或多种治疗药物也可以存在于藻酸盐凝胶或管腔中。 藻酸盐药物递送系统的活性是高度可调节的，从而可以根据需要控制释放。 释放药物的速度和释放药物的浓度可以通过变化来调整; 藻酸盐管的层数，管的开放或封闭端的数量，或包含药物的管层的数量。

公开(公告)号：US20120225889A1

公开(公告)日：2012-09-06

申请号：US13510552

申请日：2010-11-15

申请人： Asha Kulkarni-Almeida ,  Ravindra Dattatraya Gupte ,  Nilesh Madhukar Dagia ,  Prabha Beerchandra Mishra

发明人： Asha Kulkarni-Almeida ,  Ravindra Dattatraya Gupte ,  Nilesh Madhukar Dagia ,  Prabha Beerchandra Mishra

IPC分类号： A61K31/335 ,  A61P29/00 ,  A61P19/02 ,  A61P19/10 ,  A61P31/00 ,  A61P9/10 ,  A61P9/00 ,  A61P25/00 ,  A61P27/02 ,  A61P31/14 ,  A61P33/06 ,  A61P3/00 ,  A61P17/06 ,  A61P15/00 ,  A61P31/18 ,  A61P37/06 ,  A61P11/00 ,  A61P35/00 ,  A61P3/10 ,  A61P19/08 ,  A61P17/00 ,  A61P25/28 ,  A61P37/08 ,  A61P11/06 ,  A61K31/496 ,  A61K31/4523 ,  A61K31/4545 ,  A61P1/00

CPC分类号： A61K31/365 ,  Y02A50/411

摘要： The present invention provides use of the compounds represented by formula (1): wherein, R1, R2, R3 and R4 are as defined in the specification, in all their stereo isomeric and tautomeric forms and mixtures thereof in all ratios, and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable polymorphs and prodrugs and pharmaceutical compositions containing them for treatment of inflammatory disorders mediated by one or more cytokines selected from Tumor Necrosis Factor-alpha (TNF-α), interferon-γ (IFN-γ) and interleukins such as IL-1β, IL-2, IL-6, and IL-8. The present invention also relates to a pharmaceutical composition adapted for use in the treatment of inflammatory disorders. The present invention further provides a method of treatment of inflammatory disorders by administering a therapeutically effective amount of the said compound of formula (1) or its pharmaceutical composition, to a mammal in need thereof.

摘要翻译： 本发明提供由式（1）表示的化合物的用途：其中R1，R2，R3和R4如说明书中所定义，具有所有比例的所有立体异构体和互变异构形式及其混合物及其药学上可接受的 盐，药学上可接受的溶剂化物，药学上可接受的多晶型物和前药以及含有它们的药物组合物，用于治疗由一种或多种选自肿瘤坏死因子-α（TNF-α），干扰素-γ（IFN-γ）和白细胞介素 例如IL-1和bgr; IL-2，IL-6和IL-8。 本发明还涉及适用于治疗炎症性疾病的药物组合物。 本发明还提供了通过向有需要的哺乳动物施用治疗有效量的所述式（1）化合物或其药物组合物来治疗炎症性疾病的方法。

公开(公告)号：US08163730B2

公开(公告)日：2012-04-24

申请号：US12854761

申请日：2010-08-11

申请人： Bansi Lal ,  Somesh Sharma ,  Usha Ghosh ,  Swati Bal-Tembe ,  Tulsidas More ,  Asha Kulkarni-Almeida ,  Sapna Parikh ,  Radha Bhaskar Panicker ,  Anagha Damre ,  Ravindra Gupte

发明人： Bansi Lal ,  Somesh Sharma ,  Usha Ghosh ,  Swati Bal-Tembe ,  Tulsidas More ,  Asha Kulkarni-Almeida ,  Sapna Parikh ,  Radha Bhaskar Panicker ,  Anagha Damre ,  Ravindra Gupte

IPC分类号： A61K31/554 ,  C07D281/16

CPC分类号： C07D327/02

摘要： Compounds of formula 1: are disclosed, wherein V is CH2; W is S(O)m; m is the integer 0, 1 or 2; U is O, C(O), CR13R14 or NR15; where R13 is H, alkyl; R14 is H, OH, OR13 or OCOR13; R15 is H, alkyl, cycloalkyl, alkenyl, C(O)R13, C(O)OR13 or alkylaminocarbonyl; R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein. These compounds are inhibitors of tumor necrosis factor-alpha (TNF-α) and are useful as medicaments for the treatment and prevention of disorders caused by increased TNF-α activity, in particular inflammations.

摘要翻译： 公开了式1化合物，其中V是CH 2; W为S（O）m; m是整数0,1或2; U是O，C（O），CR 13 R 14或NR 15; 其中R 13为H，烷基; R14是H，OH，OR13或OCOR13; R 15是H，烷基，环烷基，烯基，C（O）R 13，C（O）OR 13或烷基氨基羰基; R1，R2，R3，R4，R5，R6，R7和R8如本文所定义。 这些化合物是肿瘤坏死因子-α（TNF-α）的抑制剂，可用作治疗和预防由增加的TNF-α活性引起的疾病，特别是炎症的药物。

公开(公告)号：US08137708B2

公开(公告)日：2012-03-20

申请号：US12520198

申请日：2007-02-20

申请人： Kalpana Sanjay Joshi ,  Vilas Wagh ,  Somesh Sharma

发明人： Kalpana Sanjay Joshi ,  Vilas Wagh ,  Somesh Sharma

IPC分类号： A01N65/00

CPC分类号： A61K36/67 ,  A61K9/009 ,  A61K9/1617 ,  A61K9/1623

摘要： A herbal composition comprising a therapeutically effective amount of the extract of Piper betle leaves as an active ingredient either alone, or with a pharmaceutically acceptable excipient. A process for the preparation of the herbal composition is provided. The herbal composition is adapted for the treatment of chronic myeloid leukemia (CML; chronic myelogenous leukemia) showing resistance to treatment with imatinib (Gleevec® or Glivec®).

摘要翻译： 一种草药组合物，其包含治疗有效量的Pi叶提取物作为单独的活性成分或与药学上可接受的赋形剂。 提供了一种制备草药组合物的方法。 草药组合物适用于治疗显示对伊马替尼治疗（Gleevec或Glivec）的抗性的慢性骨髓性白血病（CML;慢性骨髓性白血病）。

公开(公告)号：US08003602B2

公开(公告)日：2011-08-23

申请号：US12226403

申请日：2007-04-10

申请人： Girish Badrinath Mahajan ,  Saji David George ,  Prafull Vasant Ranadive ,  Prabhu Dutt Satyanarayan Mishra ,  Sreekumar Sankaranarayanan Eyyammadichiyil ,  Rajan Mukund Panshikar ,  Satish Namdeo Sawant ,  Sridevi Krishna ,  Meenakshi Sivakumar ,  Koteppa Pari ,  Becky Mary Thomas ,  Zarine Eruch Patel ,  Ram Vishwakarma ,  Chandrakant Govind Naik ,  Lisette D'Souza ,  Prabha Devi

发明人： Girish Badrinath Mahajan ,  Saji David George ,  Prafull Vasant Ranadive ,  Prabhu Dutt Satyanarayan Mishra ,  Sreekumar Sankaranarayanan Eyyammadichiyil ,  Rajan Mukund Panshikar ,  Satish Namdeo Sawant ,  Sridevi Krishna ,  Meenakshi Sivakumar ,  Koteppa Pari ,  Becky Mary Thomas ,  Zarine Eruch Patel ,  Ram Vishwakarma ,  Chandrakant Govind Naik ,  Lisette D'Souza ,  Prabha Devi

IPC分类号： A61K38/12

CPC分类号： A61K38/12 ,  C07K5/0821

摘要： This invention relates to a novel purified compound PM181104, of formula: of molecular weight 1514 and molecular formula C69H66N18O13S5; which is obtained by fermentation of the microorganism belonging to Kocuria species (ZMA B-1/MTCC 5269). The invention includes all stereoisomeric forms and all tautomeric forms of the compound PM181104 and pharmaceutically acceptable salts and derivatives such as esters and ethers. The present invention further relates to processes for the production of the novel antibacterial compound(s), to the production of the microorganism belonging to Kocuria species (ZMA B-1/MTCC 5269), and to pharmaceutical compositions containing the novel compound(s) as an active ingredient and its/their use in medicines for treatment and prevention of diseases caused by bacterial infections.

摘要翻译： 本发明涉及分子量为1514和分子式C69H66N18O13S5的新型纯化的化合物PM181104; 其通过发酵属于Kocuria物种（ZMA B-1 / MTCC 5269）的微生物获得。 本发明包括化合物PM181104的所有立体异构体形式和所有互变异构形式以及药学上可接受的盐和衍生物如酯和醚。 本发明还涉及生产新型抗菌化合物的方法，用于生产属于Kocuria种的微生物（ZMA B-1 / MTCC 5269），以及含有新化合物的药物组合物， 作为活性成分及其在用于治疗和预防由细菌感染引起的疾病的药物中的用途。

公开(公告)号：US20110151469A1

公开(公告)日：2011-06-23

申请号：US12964417

申请日：2010-12-09

申请人： SUNITA SHANKAR ,  URVI VED ,  SOMESH SHARMA

发明人： SUNITA SHANKAR ,  URVI VED ,  SOMESH SHARMA

IPC分类号： C12Q1/68 ,  G01N33/574

CPC分类号： G01N33/57496 ,  C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N2333/555 ,  G01N2500/04

摘要： The present invention relates to a method employing Interferon Epsilon (IFNE1) as a therapeutic response, prognostic, or pharmacodynamic marker for cancer chemotherapeutic treatment involving the use of cyclin dependent kinase (CDK) inhibitors. The inventors have identified IFNE1 as a biomarker transcript that is upregulated when cancer cells are treated with CDK inhibitors. In an embodiment, the method of the invention includes measuring a level of IFNE1 mRNA or IFNE1 protein in a subject's tumor, blood or other tissue. An increase in the level of IFNE1 compared to control level can indicate that the CDK inhibitor has produced a therapeutic response or can determine whether a tumor is sensitive to a CDK inhibitor.

摘要翻译： 本发明涉及使用干扰素Epsilon（IFNE1）作为涉及使用细胞周期蛋白依赖性激酶（CDK）抑制剂的癌症化学治疗的治疗反应，预后或药效学标记物的方法。 本发明人已经将IFNE1鉴定为当用CDK抑制剂治疗癌细胞时上调的生物标志物转录物。 在一个实施方案中，本发明的方法包括测量受试者的肿瘤，血液或其它组织中IFNE1 mRNA或IFNE1蛋白的水平。 与对照水平相比，IFNE1水平的增加可以表明CDK抑制剂产生治疗反应或可以确定肿瘤是否对CDK抑制剂敏感。

公开(公告)号：US07951961B2

公开(公告)日：2011-05-31

申请号：US12307645

申请日：2006-07-07

申请人： Meenakshi Sivakumar ,  Manoj Shukla ,  Pramod Kumar Jadhav ,  Ajit Borhade

发明人： Meenakshi Sivakumar ,  Manoj Shukla ,  Pramod Kumar Jadhav ,  Ajit Borhade

IPC分类号： C07D295/00

CPC分类号： C07D207/08 ,  C07D405/04

摘要： The present invention relates to an enantioselective synthesis of (+)-trans enantiomer of pyrrolidines substituted with flavones, represented by Formula 1 or salts thereof, which are inhibitors of cyclin dependant kinases and can be used for treatment of proliferative disorders such as cancer wherein Ar has the meaning as indicated in the claims.

摘要翻译： 本发明涉及用作为细胞周期蛋白依赖性激酶抑制剂的式1或其盐所代表的黄酮取代的吡咯烷的（+） - 反式对映异构体的对映选择性合成，可用于治疗增殖性疾病如癌症，其中Ar 具有如权利要求中所示的含义。

公开(公告)号：US07834052B2

公开(公告)日：2010-11-16

申请号：US11667580

申请日：2005-11-08

申请人： Bansi Lal ,  Usha Ghosh ,  Swati Bal-Tembe ,  Tulsidas More ,  Pravin Gagare ,  Sunil Jadhav ,  Shashikant Patil

发明人： Bansi Lal ,  Usha Ghosh ,  Swati Bal-Tembe ,  Tulsidas More ,  Pravin Gagare ,  Sunil Jadhav ,  Shashikant Patil

IPC分类号： A61K31/38 ,  C07D497/00

CPC分类号： C07D327/02

摘要： Compounds of formula 1: are disclosed, wherein V is CH2; W is S(O)m; m is the integer 0, 1 or 2; U is O, C(O), CR13R14 or NR15; where R13 is H, alkyl; R14 is H, OH, OR13 or OCOR13; R15 is H, alkyl, cycloalkyl, alkenyl, C(O)R13, C(O)OR13 or alkylaminocarbonyl; R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein. These compounds are inhibitors of tumor necrosis factor-alpha (TNF-α) and are useful as medicaments for the treatment and prevention of disorders caused by increased TNF-α activity, in particular inflammations.

摘要翻译： 公开了式1化合物，其中V是CH 2; W为S（O）m; m是整数0,1或2; U是O，C（O），CR 13 R 14或NR 15; 其中R 13为H，烷基; R14是H，OH，OR13或OCOR13; R 15是H，烷基，环烷基，烯基，C（O）R 13，C（O）OR 13或烷基氨基羰基; R1，R2，R3，R4，R5，R6，R7和R8如本文所定义。 这些化合物是肿瘤坏死因子-α（TNF-α）的抑制剂，可用作治疗和预防由增加的TNF-α活性引起的疾病，特别是炎症的药物。

公开(公告)号：US07635493B2

公开(公告)日：2009-12-22

申请号：US11883599

申请日：2005-06-17

申请人： Vijay Singh Chauhan ,  Kalkunte S. Satyan ,  Kavita P. Kadam

发明人： Vijay Singh Chauhan ,  Kalkunte S. Satyan ,  Kavita P. Kadam

IPC分类号： A61K36/00

CPC分类号： A61K36/9068 ,  A01N65/00 ,  A01N65/08 ,  A01N65/10 ,  A01N65/12 ,  A01N65/28 ,  A01N65/32 ,  A01N65/42 ,  A01N65/48 ,  A01N2300/00

摘要： Compositions containing extract of hedychium spicatum are useful for treating Tinea infections by topical application. Extracts from rhizomes of hedychium spicatum are particularly useful.

摘要翻译： 含有枸杞提取物的组合物可用于通过局部施用治疗癣感染。 枸杞根茎提取物特别有用。